Taysha Gene Therapies, Inc. · NASDAQ:TSHA
Taysha Gene Therapies — Investor Day (June 2021)
89 slides from Taysha Gene Therapies's investor day presentation, Jun 29, 2021
Slide 1: Research & Development Day, Day 2
RESEARCH & DEVELOPMENT DAY DAY 2 – June 29, 2021 | 9:00 AM – 12:00 PM CT Bringing New Cures to Life Exhibit 99.1
Slide 2: Legal disclosure: forward-looking statements
Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operation
Slide 3: Introductions
Introductions RA Session II President, Founder & CEO
Slide 4: TSHA-104 for SURF1-Associated Leigh Syndrome
TSHA-104 for SURF1-Associated Leigh Syndrome TSHA-104 SURF1 deficiency Steven Gray, PhD Chief Scientific Advisor, UTSW Gene Therapy Program Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D
Slide 5: SURF1 deficiency is the most common cause of Leigh syndrome
TSHA-104 SURF1 deficiency SURF1 deficiency is the most common cause of Leigh syndrome A monogenic mitochondrial disorder Most common cause of cytochrome c oxidase deficient Leigh syndrome Leigh syndrome – severe neurological disorder that presents in the first year of life Initially often presents w
Slide 6: SURF1 deficiency: most challenging symptoms reported by caregivers
SURF1 deficiency – the most challenging symptoms as reported by families and caregivers Breathing (3 caregivers) Breathing issues (x3) Strength (6 caregivers) Muscle weakness (x4) Inability to sit (x3) Head and trunk control (x2) Inability to stand Movement and motor skills (8 caregivers) Loss of ba
Slide 7: SURF1 natural history study: initial symptoms
SURF1 deficiency natural history study – Initial symptoms Review of 44 cases with SURF1 deficiency Median age for first symptom onset was 9.5 months (range 0–60 months); majority presented in the first year (32/44, 73%) Most frequently noted initial symptoms included poor feeding/vomiting (frequentl
Slide 8: SURF1 natural history study: major clinical features
SURF1 deficiency natural history study – Major clinical features Symptoms occurring in ~80%+: vomiting/feeding problems, growth failure, hypotonia, developmental delay and respiratory failure. Median time to onset of most symptoms was 1-2 years TSHA-104 SURF1 deficiency Wedatilake et al. Orphanet J
Slide 9: SURF1 natural history study: survival
SURF1 deficiency natural history study – Survival Among 44 patients with detailed clinical data, 5 were alive at time of writing (ages 2–19 years); current vital status was unknown for 3 Of the 36 deceased patients with known cause of death, the cause was central respiratory failure in 29/36 (80%) S
Slide 10: TSHA-104 AAV9 design
AAV9 capsid Brain tropism & favorable safety profile TSHA-104 IND/CTA submission expected by YE 2021 Recombinant AAV9 viral vector with engineered transgene encoding the human SURF1 protein Designed to deliver a functional copy of the SURF1 gene Received orphan drug and rare pediatric disease design
Slide 11: Slight increase in COX1 activity improved clinical phenotype
Slight increase in COX1 activity significantly improved clinical phenotype Of 17 samples, 14 were assayed 8 Leigh syndrome & 6 healthy donors (hets) Severely affected individuals had roughly 50% of normal activity Mildly affected individuals had roughly 58% of normal activity A relatively small diff
Slide 12: Reduction in COX activity correlated with disease worsening
Reduction in COX activity correlated with disease worsening – Patient fibroblast data TSHA-104 SURF1 deficiency Mild Healthy (Het) Severe
Slide 13: Vector transduction efficiency and efficacy, Part I
Vector transduction efficiency and efficacy – Part I COX activity assay in various tissues RNAScope for hSURF1opt mRNA expression COX content level using MT-CO1 protein as marker TSHA-104 SURF1 deficiency
Slide 14: TSHA-104 increased COX1 activity in SURF1 KO mice
TSHA-104 increased COX1 activity in brain and muscle in dose-dependent manner in SURF1 KO mice Ling Q et al. ASGCT 2020 TSHA-104 SURF1 deficiency * * Relative Activity * Relative Activity Change in relative COX1 activity * * Relative Activity
Slide 15: Improvement in MT-CO1 abundance post-injection
Improvement in MT-CO1 abundance 4 weeks post-injection TSHA-104 SURF1 deficiency
Slide 16: COX activity correlated with histological COX content
Biochemical COX activity correlated with histological COX content level TSHA-104 SURF1 deficiency
Slide 17: Efficacy Part II: long-term rescue
Efficacy Part II – Long-term rescue TSHA-104 SURF1 deficiency
Slide 18: TSHA-104 restored blood lactate elevation on exercise
TSHA-104 restored elevation of blood lactate on exhaustive exercise in dose-dependent manner in SURF1 KO mice D lactate 10 months Change in lactate (post exhaustion lactate-pre-exhaustion lactate) of mice from all tested groups at 10 months old. Data shown as mean +SEM **p<0.01, ***p<0.001, and ****
Slide 19: Non-GLP toxicology in mice and summary
Non-GLP Toxicology in Mice No significant differences detected in viral vector-treated animals 4 weeks post-dosing No severe damages detected in tissue integrity 12 months post-injection, some mild abnormalities mostly due to aging Summary Efficacy in SURF1 KO Mice Effectively induced mRNA expressio
Slide 20: TSHA-104 Phase 1/2 study design plan
TSHA-104 Phase 1/2 study design plan TSHA-104 SURF1 deficiency Goals and Targets of Trial Product Details and Dose Cohorts Route and Method of Administration Dose Cohorts Participants below the age of 4 years will receive a calculated dose based on brain volume 5 x 1014 total vg (n=4) Goals Primary
Slide 21: TSHA-104 study clinical assessments
TSHA-104 study clinical assessments Disease-Specific/Global Assessments Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Gross Motor Function Measure (GMFM) Swallowing / Dysphagia Assessment Seizure Diary 100-Meter Walk Test Pediatric Balance Scale (PBS) Head Control Scale Scale for the Asse
Slide 22: Anticipated next steps for TSHA-104
Anticipated next steps for TSHA-104 TSHA-104 SURF1 deficiency Complete GMP manufacturing using commercial process Submit IND/CTA in 2H 2021 Initiate Phase 1/2 interventional study by YE 2021 Continue enrollment in natural history study Complete IND-enabling toxicology study
Slide 23: Q & A
Q & A TSHA-104 SURF1 deficiency
Slide 24: TSHA-105 for SLC13A5 Deficiency
TSHA-105 for SLC13A5 Deficiency TSHA-105 SLC13A5 deficiency Rachel Bailey, PhD UTSW Gene Therapy Program Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D
Slide 25: SLC13A5 deficiency is a rare autosomal recessive disorder
SLC13A5 deficiency is a rare autosomal recessive disorder Bi-allelic loss of function in the SLC13A5 gene, resulting in a loss or reduction in citrate transport and aberrant cellular metabolism Patients have impaired motor function, speech production and seizures Signs and symptoms include seizures
Slide 26: SLC13A5 involvement in citrate transport
SLC13A5 involvement in citrate transport Disorder caused by mutations in both copies of the SLC13A5 gene which codes for a sodium dependent citrate transporter (NaCT) SLC13A5 mutations greatly reduce or eliminate citrate transporter activity Citrate is a key metabolite and plays an important role in
Slide 27: SLC13A5 deficiency results in persistent seizures and developmental delays
SLC13A5 deficiency results in persistent seizures and developmental delays Seizures Affected children present with seizures within a few days of birth which persist throughout life Multiple seizure types; Anti-epileptic drugs (phenobarbital, valproate, and acetazolamide) have varying success in cont
Slide 28: TSHA-105 in IND/CTA-enabling studies
TSHA-105 currently in IND/CTA-enabling studies Self-complementary AAV9 expressing human SLC13A5 protein under the control of a ubiquitous promoter Delivered intrathecally Currently in IND/CTA-enabling studies TSHA-105 SLC13A5 deficiency AAV9 capsid CNS tropism & favorable safety profile scAAV ITR Co
Slide 29: TSHA-105 decreased plasma citrate levels in KO mice
TSHA-105 decreased plasma citrate levels in 3-month old SLC13A5 KO mice Bailey, R. 2020 TSHA-105 SLC13A5 deficiency 0.0 0.6 0.8 0.4 0.2 WT KO Citrate (mM) * KO + AAV9 CSF KO Veh ** Months Post-injection 0.0 0.6 0.8 0.4 0.2 Citrate (mM)
Slide 30: TSHA-105 improved EEG activity in KO mice
TSHA-105 improved EEG activity in 3-month old SLC13A5 KO mice TSHA-105 SLC13A5 deficiency Bailey, R. 2020 WT + Vehicle KO + Vehicle KO + TSHA-105 CSF CSF Dark Cycle
Slide 31: PTZ seizure severity and death
PTZ - pentylenetetrazol TSHA-105 SLC13A5 deficiency Bailey, R. 2020 Seizure Severity Death KO + Vehicle (n=9) KO + TSHA-105 CSF (n=6) WT + Vehicle (n=8)
Slide 32: Moving TSHA-105 towards clinical study
Moving TSHA-105 towards clinical study – Clinical considerations TSHA-105 has received US orphan drug and rare pediatric disease designations Currently conducting IND/CTA-enabling studies for the TSHA-105 program Patients will roll in from ongoing prospective natural history study Current clinical t
Slide 33: Anticipated next steps for TSHA-105
Anticipated next steps for TSHA-105 TSHA-105 SLC13A5 deficiency Complete GMP manufacturing using commercial process Pre-IND/CTA meeting anticipated 2H 2021 Continue enrollment in natural history study Complete IND-enabling preclinical work
Slide 34: Q & A
Q & A TSHA-105 SLC13A5 deficiency
Slide 35: TSHA-103 for SLC6A1 Haploinsufficiency Disorder
TSHA-103 for SLC6A1 Haploinsufficiency Disorder TSHA-103 SLC6A1 Steven Gray, PhD Chief Scientific Advisor, UTSW Gene Therapy Program Kim Goodspeed, MD UTSW Gene Therapy Program
Slide 36: SLC6A1 haploinsufficiency disorder results in persistent seizures and delays
SLC6A1 haploinsufficiency disorder results in persistent seizures and developmental delays Autosomal dominant genetic disorder characterized by the loss of function of one copy of the SLC6A1 gene SLC6A1 encodes the GABA transporter protein type 1 (GAT1), which is responsible for the reuptake of GABA
Slide 37: SLC6A1 Patient Video
SLC6A1 Patient Video CONFIDENTIAL
Slide 38: SLC6A1 Patient Video
SLC6AI1 Patient Video
Slide 39: SLC6A1 disorder: developmental abilities and seizure types
SLC6A1 haploinsufficiency disorder results in persistent seizures and developmental delays Based on review of 116 cases, developmental abilities are variable from mild learning disability to severe developmental delay or intellectual disability Initial cases highlighted myoclonic-atonic seizures; ho
Slide 40: Qualitative EEG findings in SLC6A1 disorder
Qualitative EEG findings demonstrated abnormalities with generalized epileptiform discharges being the most prevalent TSHA-103 SLC6A1 Goodspeed K et al. Brain Comm 2020
Slide 41: Vineland and autism questionnaire results
SLC6A1 haploinsufficiency disorder results in persistent seizures and developmental delays Vineland Adaptive Behavior Scale demonstrates deficits across all four domains Autism spectrum disorder questionnaires demonstrate elevated scores, with higher scores on the Social Responsiveness Scale Manuscr
Slide 42: TSHA-103 in IND/CTA-enabling studies
TSHA-103 in IND/CTA-enabling studies Self-complementary AAV9 viral vector designed to deliver a functional copy of hSLC6A1 Proof-of-concept demonstrated in knockout SLC6A1 mouse model Delivered intrathecally Received orphan drug and rare pediatric disease designations Currently in IND/CTA-enabling s
Slide 43: SLC6A1 KO mouse phenotype
SLC6A1 KO mouse phenotype TSHA-103 SLC6A1 Decreased body weight Tremor Hindlimb clasping Rotarod Poor motor coordination Open Field Anxious behavior Nest building Decreased nest building score = autism-like phenotype Context fear conditioning Poor learning and memory Abnormal EEG Absence seizure-lik
Slide 44: Neonatal ICV TSHA-103 rescued abnormal EEG
TSHA-103 ees) Neonatal ICV administration of TSHA-103 rescued abnormal EEG in SLCGAL SLC6A1 KO and heterozygous mouse models KO + vehicle KO «TSHA-103 | sé psp: iene oedema
Slide 45: Neonatal ICV TSHA-103 rescued abnormal EEG in KO and heterozygous mice
Neonatal ICV administration of TSHA-103 rescued abnormal EEG in SLC6A1 KO and heterozygous mouse models *** N= 9 9 N= 8 5 ** TSHA-103 SLC6A1 Treated Treated
Slide 46: Anticipated next steps for TSHA-103
Anticipated next steps for TSHA-103 TSHA-103 SLC6A1 Animal proof-of-concept achieved in KO mouse model Evaluate dose response and age response & finalize dose from pharmacology Natural history study initiated by patient advocacy foundation Interventional trial protocol development underway
Slide 47: Q & A
Q & A TSHA-103 SLC6A1
Slide 48: TSHA-112 for Adult Polyglucosan Body Disease
TSHA-112 for Adult Polyglucosan Body Disease TSHA-112 APBD Berge Minassian, MD Chief Scientific Advisor, UTSW Gene Therapy Program Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D
Slide 49: Adult polyglucosan body disease (APBD)
Adult polyglucosan body disease (APBD) Caused by a mutation in the GBE1 gene, responsible for the creation of branches during glycogen synthesis Reduction in glycogen synthesis yields elongated glycogen changes that form poorly soluble aggregates in the liver, muscle and CNS Prime of life disease, w
Slide 50: TSHA-112 expected to advance in IND/CTA-enabling studies
TSHA-112 expected to advance in IND/CTA-enabling studies in 2021 Recombinant AAV9 viral vector designed for miRNA-mediated knockdown of the GYS1 gene to treat APBD Self-complementary AAV capsid (scAAV) for rapid activation and stable expression CBh promoter drives high levels of expression Currently
Slide 51: TSHA-112 reduced GYS1 expression in APBD KO model
TSHA-112 reduced GYS1 expression in the APBD KO model TSHA-112 APBD PBS miRNA 0.0 0.2 0.4 0.6 0.8 1.0 * Relative Expression of GYS1 PBS miRNA GYS1 GFP SatinFree miRNA PBS
Slide 52: TSHA-112 decreased polyglucosan body formation in hippocampus
TSHA-112 decreased polyglucosan body formation in mice hippocampus TSHA-112 APBD miRNA PBS 0 2 4 6 8 P B % i n H i p p o c a m p u s ** TSHA-112 decreased polyglucosan body formation in the hippocampus PB% in Hippocampus
Slide 53: Anticipated next steps for TSHA-112
Anticipated next steps for TSHA-112 TSHA-112 APBD Animal proof-of-concept achieved in KO mouse model Evaluate dose response and age response & finalize dose from pharmacology Interventional trial protocol development underway
Slide 54: Q & A
Q & A TSHA-112 APBD
Slide 55: TSHA-111 for Lafora Disease
TSHA-111 for Lafora Disease TSHA-111 Lafora disease Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D Berge Minassian, MD Chief Scientific Advisor, UTSW Gene Therapy Program
Slide 56: Lafora disease is a progressive and fatal neurodegenerative disorder
Lafora disease is a progressive and fatal neurodegenerative disorder Inherited, severe form of progressive myoclonus epilepsy Caused by loss of function mutations in the EPM2A (laforin) or EPM2B (malin) genes responsible for glycogen metabolism Absence of laforin or malin results in aggregates of po
Slide 57: Examples of polyglucosan bodies
Examples of polyglucosan bodies TSHA-112 APBD
Slide 58: TSHA-111 Lafora disease
TSHA-111 Lafora disease
Slide 59: Chelsea after Lafora disease diagnosis
Chelsea after Lafora disease diagnosis TSHA-111 Lafora disease
Slide 60: Lafora Patient Video
Lafora Patient Video
Slide 61: TSHA-111-Laforin and TSHA-111-Malin miRNA approaches
TSHA-111-LAFORIN and TSHA-111-MALIN, miRNA approaches Recombinant AAV9 viral vector designed for miRNA-mediated knockdown of the GYS1 gene GYS1 knockdown designed to reduce Lafora bodies and improve clinical condition Self-complementary AAV capsid (scAAV) for rapid activation and stable expression C
Slide 62: TSHA-111 reduced GYS1 expression in laforin and malin KO models
TSHA-111-LAFORIN and TSHA-111-MALIN reduced GYS1 expression in the laforin and malin KO models TSHA-111 Lafora disease malin malin knockout model PBS miRNA laforin knockout model GYS1 GFP SatinFree PBS miRNA laforin GYS1 GFP SatinFree PBS miRNA PBS miRNA Relative Expression of GYS1 Relative Expressi
Slide 63: TSHA-111 decreased Lafora body formation in mice brain
TSHA-111-LAFORIN and TSHA-111-MALIN decreased Lafora body formation in mice brain malin miRNA PBS 0 2 4 6 8 L B i n i p p o c a m p u s * laforin miRNA PBS 0 2 4 6 8 L B % i n H i p p o c a m p u s *** LB % in Hippocampus Knockdown of GYS1 decreased lafora bodies LB % in Hippocampus TSHA-111 Lafora
Slide 64: Anticipated next steps for TSHA-111
Anticipated next steps for TSHA-111-LAFORIN and TSHA-111-MALIN TSHA-111 Lafora disease Animal proof-of-concept achieved in KO mouse model Evaluate dose response and age response & finalize dose from pharmacology Interventional trial protocol development underway
Slide 65: Q & A
Q & A TSHA-111 Lafora disease
Slide 66: TSHA-113 for Tauopathies
TSHA-113 for Tauopathies TSHA-113 MAPT Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D Rachel Bailey, PhD UTSW Gene Therapy Program
Slide 67: Tauopathies: Microtubule associated Protein Tau (MAPT)
Tauopathies – Microtubule associated Protein Tau (MAPT) Tauopathies are characterized by the accumulation of toxic tau protein in the brain that results in widespread neuronal dysfunction and loss Tau accumulation is thought to underpin several neurodegenerative diseases, including Alzheimer’s, fron
Slide 68: TSHA-113 in preclinical development
TSHA-113 in preclinical development Self-complementary AAV9 viral vector for rapid activation and stable expression Utilizes AAV-mediated gene silencing to deliver life-long reduction of tau protein levels in neurons following administration of a single dose U6 promoter drives ubiquitous expression
Slide 69: Our approach to treat MAPT
Our approach to treat MAPT We are employing tau-specific miRNA shuttles that have been designed to target mRNA for all six isoforms of tau found in the human brain and/or mouse brain TSHA-113 MAPT
Slide 70: Primary screen of human tau miRNA candidates
Primary screen of human tau miRNA candidates Scr = scrambled tau miRNA; hTau = human-specific tau miRNA TSHA-113 MAPT Human MAPT Knockdown Relative Renilla/Firefly HumanTau miRNA Candidates Secondary screening of top candidates: hTau4i, hTau5i, and hTau7i
Slide 71: TSHA-113 reduced tau expression
TSHA-113 reduced tau expression TSHA-113 MAPT hTau4i hTau5i miRNA Shuttles hTau7i
Slide 72: Tau mice dosed with TSHA-113 showed GFP expression in neurons and glia
Tau mice dosed with TSHA-113 demonstrated function and GFP expression in neurons and glia TSHA-113 MAPT scAAV9/Tau5i-CBh-GFP Vehicle Relative hMAPT/GAPDH 0.0 0.5 1.0 1.5 * hTau5i Vehicle GFP Phospho-Tau
Slide 73: Anticipated next steps for TSHA-113
Anticipated next steps for TSHA-113 TSHA-113 MAPT Animal proof-of-concept achieved in KO mouse model Evaluate dose response and age response & finalize dose from pharmacology Interventional trial protocol development underway
Slide 74: Q & A
Q & A TSHA-113 MAPT
Slide 75: TSHA-106 for Angelman Syndrome
TSHA-106 for Angelman Syndrome TSHA-106 Angelman Syndrome Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM Chief Medical Officer and Head of R&D
Slide 76: Angelman syndrome is a rare, neurogenic disorder due to genomic imprinting
Angelman syndrome is a rare, neurogenic disorder due to genomic imprinting Caused by a deletion or loss of function of the maternally inherited allele of the UBE3A gene resulting in loss of the UBE3Q protein expression in neurons and abnormal communications between neurons Maternal-specific inherita
Slide 77: Current treatment for Angelman syndrome
Current treatment for Angelman syndrome TSHA-106 Angelman Syndrome There is no cure for Angelman syndrome. Current treatment focuses on managing the medical and developmental issues. Anti-seizure medication to control seizures Physical therapy to help with walking and movement problems Communication
Slide 78: Molecular pathology of Angelman syndrome
Molecular pathology of Angelman syndrome UBE3A, an E3 ligase in the ubiquitin-proteasomal system, plays important roles in brain development and normal function UBE3A conjugates polyubiquitin chains to specific lysine residues in its substrates, regulating the expression and function of these protei
Slide 79: Role of UBE3A in brain development
Role of UBE3A in brain development TSHA-106 Angelman Syndrome Function of UBE3A Target of UBE3A Function of Target (Expected) Phenotypes Coactivator of the estrogen receptor (ER) Cyp26b1 Cytochrome P450 26B1 Involved in learning and memory process Ubiquitin-protein ligase Arc Activity-regulatory cyt
Slide 80: Two novel approaches to treat Angelman syndrome
Two novel approaches to treat Angelman syndrome Targeting entire Angelman syndrome population using two approaches Knockdown of UBE3A-ATS to unsilence paternal allele Gene replacement strategy on UBE3A to mimic maternal UBE3Q allele expression Currently developing both approaches www.frontiersin.org
Slide 81: Knockdown of UBE3A-ATS is established
Knockdown of UBE3A-ATS is established, placing TSHA-106 in a competitive position to advance rapidly AAV9 viral vector designed for shRNA-mediated knockdown of UBE3A-ATS, the antisense transcript governing the expression of UBE3A through the paternal allele First in human study in Angelman syndrome
Slide 82: TSHA-106 targets UBE3A-ATS transcript through shRNA knockdown
TSHA-106 targets UBE3A-ATS transcript through shRNA knockdown TSHA-106 Angelman Syndrome 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 shRNA Candidates UBE3A-ATS UBE3A 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Folds compared to control Testing in neuroblast cell line demonstrated co
Slide 83: UBE3A expression following shRNA candidate administration
UBE3A expression following administration of shRNA candidate TSHA-106 Angelman Syndrome
Slide 84: Anticipated next steps for TSHA-106
Anticipated next steps for TSHA-106 Evaluate dose response and age response & finalize dose from pharmacology Interventional trial protocol development underway Interim expression and safety data from confirmatory NHP studies TSHA-106 Angelman Syndrome
Slide 85: Q & A
Q & A Angelman Syndrome TSHA-106
Slide 86: Closing Remarks
Closing Remarks RA Session II President, Founder & CEO
Slide 87: Near-term milestones and long-term value
Focused on achieving anticipated near-term milestones in 2021 and building long-term value Gene Replacement GAN clinical program update, including 3.5 x 1014 total vg cohort GM2 gangliosidosis preliminary biomarker data in 2H 2021 CLN1 program to dose first patient in 2021 under open IND 4 open IND/
Slide 88: Upcoming Investor Mini-Series
Upcoming Investor Mini-Series Gene Replacement Manufacturing Investor Day July 27, 2021 TSHA-118 CLN1 Investor DayAugust 2021 TSHA-102 Rett syndrome Investor DaySeptember 2021
Slide 89: Taysha Gene Therapies
TAYSH GENE dA